ECONOMIC EVALUATION OF FLUOXETINE, SERTRALINE, AND ESCITALOPRAM THERAPY FOR PATIENT DIAGNOSED WITH DEPRESSIVE DISORDER
The access to proper medication for patients diagnosed with depression is still low, where only nine percent of the patients receive medical treatment. Thus, accessibility to affordable therapy is a factor to consider. This study aimed to compare the cost and effectiveness of antidepressant thera...
Saved in:
| Main Author: | |
|---|---|
| Format: | Theses |
| Language: | Indonesia |
| Online Access: | https://digilib.itb.ac.id/gdl/view/62983 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Institution: | Institut Teknologi Bandung |
| Language: | Indonesia |
| Summary: | The access to proper medication for patients diagnosed with depression is still low,
where only nine percent of the patients receive medical treatment. Thus,
accessibility to affordable therapy is a factor to consider. This study aimed to
compare the cost and effectiveness of antidepressant therapy covered by the BPJS
scheme (Fluoxetine and Sertraline) to the newer therapeutic option (Escitalopram)
in patients diagnosed with depressive disorder (F32, ICD-10).
Based on clinical effectiveness analysis, escitalopram demonstrated superiority
(10.53%) in patient with severe depression over fluoxetine (5.56%) and sertraline
(5.71%). Annual average cost per patient for sertraline, fluoxetine , and
escitalopram were IDR 244,491; 126,619; and 161,653, respectively. Simple
modeling to accommodate risperidon-fluoxetin interaction was also developed
such revealed that the addition of escitalopram into the regimen for switch therapy
from risperidone-fluoxetine could save IDR 4,911,700 anually.
|
|---|